Le Lézard
Classified in: Science and technology
Subjects: NEW PRODUCTS/SERVICES, CALENDAR OF EVENTS, TRADE SHOWS/SEMINARS/WEBINARS

NexOptic Unveils Disruptive Lightweight, Digital Binocular Technology at CES


For the audio version of today's news release please visit https://nexoptic.com/news/

VANCOUVER, British Columbia, Dec. 20, 2018 (GLOBE NEWSWIRE) -- NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE: NXO) (OTCQX: NXOPF) (FRANKFURT: E3O1), a pioneer in the category of digital lens technologies and artificial intelligence ("AI"), will be unveiling DoubleTaketm, its revolutionary binocular, at the Consumer Electronic Show (CES, January 8-11) in Las Vegas. Since 1967, CES has become the most significant stage for next-generation products to be introduced to the world's marketplace.

What separates DoubleTaketm from any other binocular product is its Blade Opticstm technology. NexOptic's patented and patent-pending suite of optical technologies has put the power of a telescope in a rugged handheld device. By utilizing dual lenses, one wide-field and one narrow-field, DoubleTaketm makes finding, focusing, and zooming in on objects far quicker, easier and more enjoyable than when using conventional products. It digitally supports 4K video, 12 MP photos, and audio with an SD card slot option. Users can also wirelessly share their media and/or display screen with smartphones. See the product in use here.

"DoubleTaketm is ideal for outdoor enthusiasts such as boaters, birders, hikers, and hunters. It's also perfect for watching sports events, taking on vacations, or to make that back-row seat a front-row seat," said John Daugela, CEO of NexOptic.

To help the company reach its target audience, NexOptic has hired Elevator North, LLC out of Hingham, MA. to lead its media relations and brand activation efforts. Members of the media will have their first opportunity to learn about NexOptic at CES Unveiled on January 6 at the Mandalay Bay in Las Vegas.

"NexOptic has developed a breakthrough technology that could make traditional binoculars obsolete," said Mark Tedeschi, Chief Marketing Officer at Elevator North. "We're thrilled to join their talented team and help tell their story to a wide range of markets." The company is on track to begin selling DoubleTaketm to consumers in 2019.

"Elevator North has a long history working with brands that speak to active, tech-savvy consumers, and we're happy to have them on the team so they can start telling our story to key dealers and targeted consumers," said Daugela.

If you'd like to schedule a meeting to preview NexOptic at CES, please contact Matt Fitzgerald at Elevator North, 781-740-4050 or at [email protected]. NexOptic will be exhibiting in the Sands, Hall G Booth 53358. For Sales inquiries contact Kerri McTaggart at 604-669-7330, Ext 304 or [email protected]

About Elevator North

Elevator North of Hingham, MA are proven experts in getting their clients in front of the right audiences. They artfully package the spirit of the brands they represent, with a variety of creative services and marketing technologies. Their disciplined, analytical process insures that launches and subsequent campaigns work to their maximum potential.

About NexOptic Technology Corp.

NexOptic is an innovative optical development company, which aims to enhance the way we view the world around us. NexOptic is aggressively pursuing a multi-pronged optical innovation strategy. The Company is engineering its first consumer product for the growing outdoor recreation market, as well as refining its demonstration lens prototype for smartphones and has created cutting-edge artificial intelligence that significantly reduces image noise and motion blur common in poor lighting environments.

Utilizing Blade Opticstm, the Company's developing suite of optical technologies, NexOptic can increase aperture sizes within given depth constraints of various imaging applications. Increasing the aperture size enables a lens system to have an improved diffraction limit, providing greatly increased resolution. Blade Opticstm refers to NexOptic's lens designs, algorithms, and mechanics, which vary from patented to patent-pending, and includes all of the Company's intellectual property and know-how.

NexOptic trades on the TSX Venture as "NXO," on the OTCQX under the symbol "NXOPF," and on Frankfurt as "E3O1." More information is available at www.nexoptic.com

On behalf of the Board of Directors

NexOptic Technology Corp.
John Daugela, CEO & Director

www.nexoptic.com
[email protected]
+1 (604) 669 ? 7330

TSX-V: NXO
OTCQX: NXOPF
Frankfurt: E3O1

Forward-Looking Statements

This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws, including, but not limited to, statements with respect to expectations concerning the development of its sports-optic device and technology, and expected results, specifications, capabilities and applications thereof. The reader is cautioned that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other factors which are difficult to predict and that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Forward-looking statements are based on the then current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates and are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations, including, among others: risks commonly associated with the development of new technologies, including that the Company's technology, product designs and prototype are at an early stage and additional work will be required to confirm potential applications and feasibility of its technologies or bring product designs to market; the Company may not be able complete product development as currently expected; potential applications of the Company's technology are based on limited studies and may not be representative of the broader market; the risk that prototypes and designs may not achieve expected results; the Company may not be able to commercialize its technology; the Company may not be able to source components for its products on a cost-effective basis; the Company may not have access to necessary financing on acceptable terms or at all; pending or future patent applications may not be approved as contemplated or at all; and other risks inherent with technology and product development and the business of the Company. Such forward-looking statements should therefore be construed considering such factors. Other than in accordance with its legal or regulatory obligations, the Company is not under any obligation and it expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

18 mai 2024
After tens of thousands of NYC children were turned away from "Summer Rising," New York City's popular, free summer enrichment program, Brains & Motion launched a campaign offering camps at NYU for a small fraction of the up-to-$1400 per week price...



News published on and distributed by: